Existing ALS treatment options are limited and largely ineffective, however the first disease modifying drug was recently approved in USA and Europe for ALS associated with the SOD1 mutation, highlighting the need for early diagnosis (Miller et al. 2022). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.